Maruyama et al. also reported that continuous INSL6 infusion can reduce isoproterenol-induced left ventricular systolic dysfunction and cardiac fibrosis by regulating liver X receptor/retinoid X receptor signaling ([4], p. e008441), suggesting that INSL6 may be a potential biomarker in cardiovascular diseases, such as myocardial infarction. This evidence concerns the gene INSL6 and myocardial infarction.